Label: PIMTREA- desogestrel/ethinyl estradiol and ethinyl estradiol kit

  • NDC Code(s): 16714-404-01, 16714-404-02, 16714-404-03, 16714-404-04
  • Packager: Northstar Rx LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 26, 2018

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION
    Rx only - Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
  • DESCRIPTION
    PIMTREA™ (desogestrel/ethinyl estradiol and ethinyl estradiol tablets) provide an oral contraceptive regimen of 21 dark blue tablets each containing 0.15 mg desogestrel ...
  • CLINICAL PHARMACOLOGY
    Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical ...
  • INDICATIONS AND USAGE
    PIMTREA™ (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral ...
  • CONTRAINDICATIONS
    Oral contraceptives should not be used in women who currently have the following conditions: • Thrombophlebitis or thromboembolic disorders - • A past history of deep vein thrombophlebitis or ...
  • WARNINGS
    The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder ...
  • PRECAUTIONS
    1. General - Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 2. Physical examination and follow up - It ...
  • INFORMATION FOR PATIENTS
    See Patient Labeling Printed Below
  • ADVERSE REACTIONS
    An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): • Thrombophlebitis and venous thrombosis with or ...
  • OVERDOSAGE
    Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in ...
  • DOSAGE AND ADMINISTRATION
    To achieve maximum contraceptive effectiveness, PIMTREA™ (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets must be taken exactly as directed and at intervals not exceeding 24 hours ...
  • HOW SUPPLIED
    PIMTREA™ (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets contain 21 round dark blue tablets, 2 round white tablets and 5 round green tablets in a blister card (NDC  16714-404-01 ...
  • REFERENCES
    1. Hatcher RA, Trussell J, Stewart F et al. Contraceptive Technology: Seventeenth Revised Edition, New York: Irvington Publishers, 1998, in press. 2. Stadel BV. Oral contraceptives and ...
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
    PimtreaTM - (Desogestrel and Ethinyl Estradiol Tablet, USP and Ethinyl Estradiol Tablets, USP) Each dark blue tablet (21) contains 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. Each white ...
  • INGREDIENTS AND APPEARANCE
    Product Information